Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit
Published . Updated .
Covered by 4 outlets: WTVB, The Mighty 790 KFGO, 1470 & 100.3 WMBD, Reuters.
Who covered it: Center 1 · Not rated 3. How we rate outlets
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Nov 4 (Reuters) - Smith+Nephew cut its full-year revenue and profit forecast on Wednesday as the British medical device maker also confirmed that talks about a potential merger with Johnson & Johnson's orthopaedics unit have ended. The forecast cut f...
Directly affected
Indirectly affected
- EWU iShares MSCI United Kingdom ETF-1.3% 30d
iShares MSCI United Kingdom ETF holds stocks listed in the UK, which this story is about (“british”).
- EFA iShares MSCI EAFE ETF-1.5% 9d
iShares MSCI EAFE ETF is a broad fund of developed-market stocks that includes the UK, which this story is about.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Johnson & Johnson belongs to, so it often moves with news about it.
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+7.8% 30d
AbbVie is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+1.9% 18d
Merck is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+6.9% 30d
Abbott Laboratories is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- PFE Pfizer+5.5% 30d
Pfizer is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SNN | -0.17% | -1.56% | base | after close | after close | after close | after close |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| EWUNo price data for this ticker | — | — | — | — | — | — | — |
| EFANo price data for this ticker | — | — | — | — | — | — | — |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| ABBVNo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
| ABTNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Smith+Nephew cuts outlook, confirms failed merger talks with J&J’s orthopaedics unit WTVB
Source: WTVB
This story
| Company | When | Move | Status |
|---|---|---|---|
| SNN | three days earlier | -1.56% | final price |
| SNN | five days earlier | -0.17% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Sen. John Boozman sold EFA (jointly held), worth $1,001 - $15,000 on 9 Sep 2026. That is 56 days before publication. Filed 21 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 51 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 33 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 47 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
50 out of 100
“Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit” scores 50 out of 100. The score uses 4 sources.